<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231003141039&amp;utm_medium=rss&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231003141039&amp;utm_medium=rss&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Tue, 03 Oct 2023 18:10:42 +0000</lastbuilddate>
<pubDate>Tue, 03 Oct 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Less concern about missing NSTEMIs, more prospective randomized controlled trials warranted</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37787622/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231003141039&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 3:ehad646. doi: 10.1093/eurheartj/ehad646. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37787622/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231003141039&v=2.17.9.post6+86293ac">37787622</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad646>10.1093/eurheartj/ehad646</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37787622</guid>
<pubDate>Tue, 03 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Cyril Camaro</dc:creator>
<dc:creator>Goaris W A Aarts</dc:creator>
<dc:creator>Niels van Royen</dc:creator>
<dc:date>2023-10-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Less concern about missing NSTEMIs, more prospective randomized controlled trials warranted</dc:title>
<dc:identifier>pmid:37787622</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad646</dc:identifier>
</item>
<item>
<title>Concern regarding missed non-ST-segment elevation myocardial infarctions when applying a single, pre-hospital cardiac troponin measurement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37787616/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231003141039&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 3:ehad642. doi: 10.1093/eurheartj/ehad642. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37787616/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231003141039&v=2.17.9.post6+86293ac">37787616</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad642>10.1093/eurheartj/ehad642</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37787616</guid>
<pubDate>Tue, 03 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Jonas Glaeser</dc:creator>
<dc:creator>Pedro Lopez-Ayala</dc:creator>
<dc:creator>Christian Mueller</dc:creator>
<dc:date>2023-10-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Concern regarding missed non-ST-segment elevation myocardial infarctions when applying a single, pre-hospital cardiac troponin measurement</dc:title>
<dc:identifier>pmid:37787616</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad642</dc:identifier>
</item>
<item>
<title>Intracoronary delivery of extracellular vesicles from human cardiac progenitor cells reduces infarct size in porcine acute myocardial infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37787585/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231003141039&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 3:ehad636. doi: 10.1093/eurheartj/ehad636. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37787585/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231003141039&v=2.17.9.post6+86293ac">37787585</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad636>10.1093/eurheartj/ehad636</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37787585</guid>
<pubDate>Tue, 03 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Maximilian Y Emmert</dc:creator>
<dc:creator>Jacopo Burrello</dc:creator>
<dc:creator>Petra Wolint</dc:creator>
<dc:creator>Monika Hilbe</dc:creator>
<dc:creator>Gabriella Andriolo</dc:creator>
<dc:creator>Carolina Balbi</dc:creator>
<dc:creator>Elena Provasi</dc:creator>
<dc:creator>Lucia Turchetto</dc:creator>
<dc:creator>Marina Radrizzani</dc:creator>
<dc:creator>Timo Z Nazari-Shafti</dc:creator>
<dc:creator>Nikola Cesarovic</dc:creator>
<dc:creator>Sebastian Neuber</dc:creator>
<dc:creator>Volkmar Falk</dc:creator>
<dc:creator>Simon P Hoerstrup</dc:creator>
<dc:creator>Rayyan Hemetsberger</dc:creator>
<dc:creator>Mariann Gyöngyösi</dc:creator>
<dc:creator>Lucio Barile</dc:creator>
<dc:creator>Giuseppe Vassalli</dc:creator>
<dc:date>2023-10-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intracoronary delivery of extracellular vesicles from human cardiac progenitor cells reduces infarct size in porcine acute myocardial infarction</dc:title>
<dc:identifier>pmid:37787585</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad636</dc:identifier>
</item>
<item>
<title>Cardiovascular benefits of fermented foods and beverages: still up for debate</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37783744/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231003141039&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Oct 2. doi: 10.1038/s41569-023-00938-3. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37783744/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231003141039&v=2.17.9.post6+86293ac">37783744</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00938-3>10.1038/s41569-023-00938-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37783744</guid>
<pubDate>Mon, 02 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Ramon Estruch</dc:creator>
<dc:creator>Rosa M Lamuela-Raventós</dc:creator>
<dc:date>2023-10-02</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Cardiovascular benefits of fermented foods and beverages: still up for debate</dc:title>
<dc:identifier>pmid:37783744</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00938-3</dc:identifier>
</item>
<item>
<title>Cardiovascular physiology and pathophysiology at high altitude</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37783743/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231003141039&amp;v=2.17.9.post6+86293ac
      <description>Oxygen is vital for cellular metabolism; therefore, the hypoxic conditions encountered at high altitude affect all physiological functions. Acute hypoxia activates the adrenergic system and induces tachycardia, whereas hypoxic pulmonary vasoconstriction increases pulmonary artery pressure. After a few days of exposure to low oxygen concentrations, the autonomic nervous system adapts and tachycardia decreases, thereby protecting the myocardium against high energy consumption. Permanent exposure...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Oct 2. doi: 10.1038/s41569-023-00924-9. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Oxygen is vital for cellular metabolism; therefore, the hypoxic conditions encountered at high altitude affect all physiological functions. Acute hypoxia activates the adrenergic system and induces tachycardia, whereas hypoxic pulmonary vasoconstriction increases pulmonary artery pressure. After a few days of exposure to low oxygen concentrations, the autonomic nervous system adapts and tachycardia decreases, thereby protecting the myocardium against high energy consumption. Permanent exposure to high altitude induces erythropoiesis, which if excessive can be deleterious and lead to chronic mountain sickness, often associated with pulmonary hypertension and heart failure. Genetic factors might account for the variable prevalence of chronic mountain sickness, depending on the population and geographical region. Cardiovascular adaptations to hypoxia provide a remarkable model of the regulation of oxygen availability at the cellular and systemic levels. Rapid exposure to high altitude can have adverse effects in patients with cardiovascular diseases. However, intermittent, moderate hypoxia might be useful in the management of some cardiovascular disorders, such as coronary heart disease and heart failure. The aim of this Review is to help physicians to understand the cardiovascular responses to hypoxia and to outline some recommendations that they can give to patients with cardiovascular disease who wish to travel to high-altitude destinations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37783743/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231003141039&v=2.17.9.post6+86293ac">37783743</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00924-9>10.1038/s41569-023-00924-9</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37783743</guid>
<pubDate>Mon, 02 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Jean-Paul Richalet</dc:creator>
<dc:creator>Eric Hermand</dc:creator>
<dc:creator>François J Lhuissier</dc:creator>
<dc:date>2023-10-02</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Cardiovascular physiology and pathophysiology at high altitude</dc:title>
<dc:identifier>pmid:37783743</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00924-9</dc:identifier>
</item>
<item>
<title>Value-Based Payment for Cardiovascular Care: Getting to the Heart of the Matter</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37782698/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231003141039&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 3;148(14):1084-1086. doi: 10.1161/CIRCULATIONAHA.123.065661. Epub 2023 Oct 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37782698/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231003141039&v=2.17.9.post6+86293ac">37782698</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065661>10.1161/CIRCULATIONAHA.123.065661</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37782698</guid>
<pubDate>Mon, 02 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Rishi K Wadhera</dc:creator>
<dc:date>2023-10-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Value-Based Payment for Cardiovascular Care: Getting to the Heart of the Matter</dc:title>
<dc:identifier>pmid:37782698</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065661</dc:identifier>
</item>
<item>
<title>Bleeding and Myocardial Infarction in Acquired Factor VIII Deficiency</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37782697/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231003141039&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 3;148(14):1127-1133. doi: 10.1161/CIRCULATIONAHA.123.063904. Epub 2023 Oct 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37782697/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231003141039&v=2.17.9.post6+86293ac">37782697</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.063904>10.1161/CIRCULATIONAHA.123.063904</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37782697</guid>
<pubDate>Mon, 02 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Joseph M Kim</dc:creator>
<dc:creator>Robert M Stern</dc:creator>
<dc:creator>Bradley A Maron</dc:creator>
<dc:date>2023-10-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Bleeding and Myocardial Infarction in Acquired Factor VIII Deficiency</dc:title>
<dc:identifier>pmid:37782697</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.063904</dc:identifier>
</item>
<item>
<title>The Time to Initiate Anti-Inflammatory Therapy for Patients With Chronic Coronary Atherosclerosis Has Arrived</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37782696/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231003141039&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 3;148(14):1071-1073. doi: 10.1161/CIRCULATIONAHA.123.066510. Epub 2023 Oct 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37782696/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231003141039&v=2.17.9.post6+86293ac">37782696</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066510>10.1161/CIRCULATIONAHA.123.066510</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37782696</guid>
<pubDate>Mon, 02 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Paul M Ridker</dc:creator>
<dc:date>2023-10-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Time to Initiate Anti-Inflammatory Therapy for Patients With Chronic Coronary Atherosclerosis Has Arrived</dc:title>
<dc:identifier>pmid:37782696</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066510</dc:identifier>
</item>
<item>
<title>Standardized Definitions for Cardiogenic Shock Research and Mechanical Circulatory Support Devices: Scientific Expert Panel From the Shock Academic Research Consortium (SHARC)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37782695/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231003141039&amp;v=2.17.9.post6+86293ac
      <description>The Shock Academic Research Consortium is a multi-stakeholder group, including representatives from the US Food and Drug Administration and other government agencies, industry, and payers, convened to develop pragmatic consensus definitions useful for the evaluation of clinical trials enrolling patients with cardiogenic shock, including trials evaluating mechanical circulatory support devices. Several in-person and virtual meetings were convened between 2020 and 2022 to discuss the need for...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 3;148(14):1113-1126. doi: 10.1161/CIRCULATIONAHA.123.064527. Epub 2023 Oct 2.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The Shock Academic Research Consortium is a multi-stakeholder group, including representatives from the US Food and Drug Administration and other government agencies, industry, and payers, convened to develop pragmatic consensus definitions useful for the evaluation of clinical trials enrolling patients with cardiogenic shock, including trials evaluating mechanical circulatory support devices. Several in-person and virtual meetings were convened between 2020 and 2022 to discuss the need for developing the standardized definitions required for evaluation of mechanical circulatory support devices in clinical trials for cardiogenic shock patients. The expert panel identified key concepts and topics by performing literature reviews, including previous clinical trials, while recognizing current challenges and the need to advance evidence-based practice and statistical analysis to support future clinical trials. For each category, a lead (primary) author was assigned to perform a literature search and draft a proposed definition, which was presented to the subgroup. These definitions were further modified after feedback from the expert panel meetings until a consensus was reached. This manuscript summarizes the expert panel recommendations focused on outcome definitions, including efficacy and safety.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37782695/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231003141039&v=2.17.9.post6+86293ac">37782695</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064527>10.1161/CIRCULATIONAHA.123.064527</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37782695</guid>
<pubDate>Mon, 02 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Ron Waksman</dc:creator>
<dc:creator>Mohit Pahuja</dc:creator>
<dc:creator>Sean van Diepen</dc:creator>
<dc:creator>Alastair G Proudfoot</dc:creator>
<dc:creator>David Morrow</dc:creator>
<dc:creator>Ernest Spitzer</dc:creator>
<dc:creator>Graham Nichol</dc:creator>
<dc:creator>Myron L Weisfeldt</dc:creator>
<dc:creator>Mauro Moscucci</dc:creator>
<dc:creator>Patrick R Lawler</dc:creator>
<dc:creator>Alexandre Mebazaa</dc:creator>
<dc:creator>Eddy Fan</dc:creator>
<dc:creator>Neal W Dickert</dc:creator>
<dc:creator>Marc Samsky</dc:creator>
<dc:creator>Robert Kormos</dc:creator>
<dc:creator>Ileana L Piña</dc:creator>
<dc:creator>Bram Zuckerman</dc:creator>
<dc:creator>Andrew Farb</dc:creator>
<dc:creator>John S Sapirstein</dc:creator>
<dc:creator>Charles Simonton</dc:creator>
<dc:creator>Nick E J West</dc:creator>
<dc:creator>Abdulla A Damluji</dc:creator>
<dc:creator>Ian C Gilchrist</dc:creator>
<dc:creator>Uwe Zeymer</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:creator>Donald E Cutlip</dc:creator>
<dc:creator>Mitchell Krucoff</dc:creator>
<dc:creator>William T Abraham</dc:creator>
<dc:date>2023-10-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Standardized Definitions for Cardiogenic Shock Research and Mechanical Circulatory Support Devices: Scientific Expert Panel From the Shock Academic Research Consortium (SHARC)</dc:title>
<dc:identifier>pmid:37782695</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064527</dc:identifier>
</item>
<item>
<title>BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in &lt;em>;Tet2&lt;/em>; Clonal Hematopoiesis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231003141039&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in TET2 CH.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 2. doi: 10.1161/CIRCULATIONAHA.123.065344. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Clonal hematopoiesis (CH) has emerged as an independent risk factor for atherosclerotic cardiovascular disease, with activation of macrophage inflammasomes as a potential underlying mechanism. The NLRP3 (NLR family pyrin domain containing 3) inflammasome has a key role in promoting atherosclerosis in mouse models of <i>Tet2</i> CH, whereas inhibition of the inflammasome product interleukin-1β appeared to particularly benefit patients with <i>TET2</i> CH in CANTOS (Cardiovascular Risk Reduction Study [Reduction in Recurrent Major CV Disease Events]). <i>TET2</i> is an epigenetic modifier that decreases promoter methylation. However, the mechanisms underlying macrophage NLRP3 inflammasome activation in TET2 (Tet methylcytosine dioxygenase 2) deficiency and potential links with epigenetic modifications are poorly understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used cholesterol-loaded TET2-deficient murine and embryonic stem cell-derived isogenic human macrophages to evaluate mechanisms of NLRP3 inflammasome activation in vitro and hypercholesterolemic <i>Ldlr</i><sup>-<i>/</i>-</sup> mice modeling <i>TET2</i> CH to assess the role of NLRP3 inflammasome activation in atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: <i>Tet2</i> deficiency in murine macrophages acted synergistically with cholesterol loading in cell culture and with hypercholesterolemia in vivo to increase JNK1 (c-Jun N-terminal kinase 1) phosphorylation and NLRP3 inflammasome activation. The mechanism of JNK (c-Jun N-terminal kinase) activation in TET2 deficiency was increased promoter methylation and decreased expression of the JNK-inactivating dual-specificity phosphatase <i>Dusp10</i>. Active Tet1-deadCas9-targeted editing of <i>Dusp10</i> promoter methylation abolished cholesterol-induced inflammasome activation in <i>Tet2</i>-deficient macrophages. Increased JNK1 signaling led to NLRP3 deubiquitylation and activation by the deubiquitinase BRCC3 (<i>BRCA1/BRCA2</i>-containing complex subunit 3). Accelerated atherosclerosis and neutrophil extracellular trap formation (NETosis) in <i>Tet2</i> CH mice were reversed by holomycin, a BRCC3 deubiquitinase inhibitor, and also by hematopoietic deficiency of Abro1, an essential scaffolding protein in the BRCC3-containing cytosolic complex. Human <i>TET2</i><sup>-<i>/</i>-</sup> macrophages displayed increased JNK1 and NLRP3 inflammasome activation, especially after cholesterol loading, with reversal by holomycin treatment, indicating human relevance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in <i>TET2</i> CH.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231003141039&v=2.17.9.post6+86293ac">37781816</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065344>10.1161/CIRCULATIONAHA.123.065344</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37781816</guid>
<pubDate>Mon, 02 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Mustafa Yalcinkaya</dc:creator>
<dc:creator>Wenli Liu</dc:creator>
<dc:creator>Leigh-Anne Thomas</dc:creator>
<dc:creator>Malgorzata Olszewska</dc:creator>
<dc:creator>Tong Xiao</dc:creator>
<dc:creator>Sandra Abramowicz</dc:creator>
<dc:creator>Eirini P Papapetrou</dc:creator>
<dc:creator>Marit Westerterp</dc:creator>
<dc:creator>Nan Wang</dc:creator>
<dc:creator>Ira Tabas</dc:creator>
<dc:creator>Alan R Tall</dc:creator>
<dc:date>2023-10-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in &lt;em>;Tet2&lt;/em>; Clonal Hematopoiesis</dc:title>
<dc:identifier>pmid:37781816</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065344</dc:identifier>
</item>
<item>
<title>Association Between Mental Health Burden, Clinical Presentation, and Outcomes in Individuals With Symptomatic Peripheral Artery Disease: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37781785/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231003141039&amp;v=2.17.9.post6+86293ac
      <description>Along with the rising burden of peripheral artery disease (PAD), mental health concerns are increasingly being recognized as a comorbidity to address in the chronic disease management of symptomatic PAD. Apart from a high prevalence of comorbid mental health conditions, the role of pain and changing health behaviors and the broader impacts of illness and adaptation to living with PAD require specialized behavioral health expertise. This scientific statement builds a case that this expertise...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 2. doi: 10.1161/CIR.0000000000001178. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Along with the rising burden of peripheral artery disease (PAD), mental health concerns are increasingly being recognized as a comorbidity to address in the chronic disease management of symptomatic PAD. Apart from a high prevalence of comorbid mental health conditions, the role of pain and changing health behaviors and the broader impacts of illness and adaptation to living with PAD require specialized behavioral health expertise. This scientific statement builds a case that this expertise should be integrated within the multidisciplinary PAD team. Furthermore, areas such as cognitive dysfunction and palliative care are highlighted as needing psychological interventions. Although much of the evidence of the efficacy of psychological and psychotropic interventions has been extrapolated from other cardiovascular populations, evidence for the role of psychological interventions for behavior change, for example, uptake of exercise regimens, is increasingly being accrued within PAD. Areas for behavioral health needs and interactions with PAD treatment are discussed, including the use of opioids, depression management, anxiety and stress reduction interventions, the use of benzodiazepines and antidepressants, smoking cessation, rehabilitation trajectories after amputation, and the role of cognitive decline for PAD treatment and outcomes. A case summary highlights the stigma around mental health and vascular disease and the fragmentation of care. This scientific statement provides remarks for building a road map for integrated behavioral PAD care and potential solutions to overcome these barriers. Instrumental to reaching these changes are interprofessional advocacy efforts and initiatives that help break down the stigma around mental health and promote evidence-based collaborative, nonhierarchical, and multidisciplinary PAD care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37781785/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231003141039&v=2.17.9.post6+86293ac">37781785</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001178>10.1161/CIR.0000000000001178</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37781785</guid>
<pubDate>Mon, 02 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Kim G Smolderen</dc:creator>
<dc:creator>Zainab Samaan</dc:creator>
<dc:creator>Carole Decker</dc:creator>
<dc:creator>Tracie Collins</dc:creator>
<dc:creator>Ronald M Lazar</dc:creator>
<dc:creator>Nathan K Itoga</dc:creator>
<dc:creator>Carlos Mena-Hurtado</dc:creator>
<dc:creator>American Heart Association Council on Peripheral Vascular Disease; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Lifestyle and Cardiometabolic Health; and Council on Quality of Care and Outcomes Research</dc:creator>
<dc:date>2023-10-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Association Between Mental Health Burden, Clinical Presentation, and Outcomes in Individuals With Symptomatic Peripheral Artery Disease: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:37781785</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001178</dc:identifier>
</item>
<item>
<title>Focus on heart failure and cardiomyopathies: new ESC Guidelines and key meta-analyses</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37778030/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231003141039&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 1;44(37):3487-3491. doi: 10.1093/eurheartj/ehad647.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37778030/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231003141039&v=2.17.9.post6+86293ac">37778030</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad647>10.1093/eurheartj/ehad647</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37778030</guid>
<pubDate>Sun, 01 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-10-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Focus on heart failure and cardiomyopathies: new ESC Guidelines and key meta-analyses</dc:title>
<dc:identifier>pmid:37778030</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad647</dc:identifier>
</item>
<item>
<title>Understanding T2MI: Thank Goodness for the Women</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37777948/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231003141039&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 18:S0735-1097(23)06470-7. doi: 10.1016/j.jacc.2023.08.021. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37777948/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231003141039&v=2.17.9.post6+86293ac">37777948</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.021>10.1016/j.jacc.2023.08.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37777948</guid>
<pubDate>Sun, 01 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>C Noel Bairey Merz</dc:creator>
<dc:creator>Martha Gulati</dc:creator>
<dc:creator>Janet Wei</dc:creator>
<dc:date>2023-10-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Understanding T2MI: Thank Goodness for the Women</dc:title>
<dc:identifier>pmid:37777948</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.021</dc:identifier>
</item>
<item>
<title>Coronary Computed Tomographic Angiography With Fractional Flow Reserve in Patients With Type 2 Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37777947/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231003141039&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Among individuals with adjudicated T2MI, CAD was prevalent, but the majority of patients had nonobstructive CAD. Mediators of ischemia are likely multifactorial in this population. (Defining the Prevalence and Characteristics of Coronary Artery Disease Among Patients with Type 2 Myocardial Infarction using CT-FFR [DEFINE TYPE 2 MI]; NCT04864119).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 18:S0735-1097(23)06469-0. doi: 10.1016/j.jacc.2023.08.020. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Type 2 myocardial infarction (T2MI) related to a supply/demand imbalance of coronary blood flow is common and associated with poor prognosis. Coronary artery disease (CAD) may predispose some individuals to T2MI and contribute to its high rate of recurrent cardiovascular events. Little is known about the presence and extent of CAD in this population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to evaluate the presence and characteristics of CAD among patients with T2MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this prospective study, consecutive eligible individuals with Fourth Universal Definition of Myocardial Infarction criteria for T2MI were enrolled. Participants underwent coronary computed tomography angiography (CTA), fractional flow reserve derived with coronary CTA (FFR<sub>CT</sub>), and plaque volume analyses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 50 participants, 25 (50%) were female, and the mean age was 68.0 ± 11.4 years. Atherosclerotic risk factors were common. Coronary CTA revealed coronary plaque in 46 participants (92%). A moderate or greater stenosis (≥50%) was identified in 42% of participants, and obstructive disease (≥50% left main stenosis or ≥70% stenosis in any other epicardial coronary artery) was present in 26%. Prevalence of obstructive CAD did not differ according to T2MI cause (P = 0.54). A hemodynamically significant focal stenosis identified by FFR<sub>CT</sub> was present in 13 participants (26%). Among participants with a stenosis ≥50% (n = 21), FFR<sub>CT</sub> excluded lesion-specific hemodynamically significant stenosis in 8 cases (38%).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among individuals with adjudicated T2MI, CAD was prevalent, but the majority of patients had nonobstructive CAD. Mediators of ischemia are likely multifactorial in this population. (Defining the Prevalence and Characteristics of Coronary Artery Disease Among Patients with Type 2 Myocardial Infarction using CT-FFR [DEFINE TYPE 2 MI]; NCT04864119).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37777947/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231003141039&v=2.17.9.post6+86293ac">37777947</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.020>10.1016/j.jacc.2023.08.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37777947</guid>
<pubDate>Sun, 01 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Cian P McCarthy</dc:creator>
<dc:creator>Sean P Murphy</dc:creator>
<dc:creator>Daniel K Amponsah</dc:creator>
<dc:creator>Paula K Rambarat</dc:creator>
<dc:creator>Claire Lin</dc:creator>
<dc:creator>Yuxi Liu</dc:creator>
<dc:creator>Reza Mohebi</dc:creator>
<dc:creator>Allison Levin</dc:creator>
<dc:creator>Avanthi Raghavan</dc:creator>
<dc:creator>Hannah Miksenas</dc:creator>
<dc:creator>Campbell Rogers</dc:creator>
<dc:creator>Jason H Wasfy</dc:creator>
<dc:creator>Ron Blankstein</dc:creator>
<dc:creator>Brian Ghoshhajra</dc:creator>
<dc:creator>Sandeep Hedgire</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:date>2023-10-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Coronary Computed Tomographic Angiography With Fractional Flow Reserve in Patients With Type 2 Myocardial Infarction</dc:title>
<dc:identifier>pmid:37777947</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.020</dc:identifier>
</item>
<item>
<title>An AsCas12f-based compact genome-editing tool derived by deep mutational scanning and structural analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37776859/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231003141039&amp;v=2.17.9.post6+86293ac
      <description>SpCas9 and AsCas12a are widely utilized as genome-editing tools in human cells. However, their relatively large size poses a limitation for delivery by cargo-size-limited adeno-associated virus (AAV) vectors. The type V-F Cas12f from Acidibacillus sulfuroxidans is exceptionally compact (422 amino acids) and has been harnessed as a compact genome-editing tool. Here, we developed an approach, combining deep mutational scanning and structure-informed design, to successfully generate two AsCas12f...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 22:S0092-8674(23)00963-7. doi: 10.1016/j.cell.2023.08.031. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">SpCas9 and AsCas12a are widely utilized as genome-editing tools in human cells. However, their relatively large size poses a limitation for delivery by cargo-size-limited adeno-associated virus (AAV) vectors. The type V-F Cas12f from Acidibacillus sulfuroxidans is exceptionally compact (422 amino acids) and has been harnessed as a compact genome-editing tool. Here, we developed an approach, combining deep mutational scanning and structure-informed design, to successfully generate two AsCas12f activity-enhanced (enAsCas12f) variants. Remarkably, the enAsCas12f variants exhibited genome-editing activities in human cells comparable with those of SpCas9 and AsCas12a. The cryoelectron microscopy (cryo-EM) structures revealed that the mutations stabilize the dimer formation and reinforce interactions with nucleic acids to enhance their DNA cleavage activities. Moreover, enAsCas12f packaged with partner genes in an all-in-one AAV vector exhibited efficient knock-in/knock-out activities and transcriptional activation in mice. Taken together, enAsCas12f variants could offer a minimal genome-editing platform for in vivo gene therapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37776859/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231003141039&v=2.17.9.post6+86293ac">37776859</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.031>10.1016/j.cell.2023.08.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37776859</guid>
<pubDate>Sat, 30 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Tomohiro Hino</dc:creator>
<dc:creator>Satoshi N Omura</dc:creator>
<dc:creator>Ryoya Nakagawa</dc:creator>
<dc:creator>Tomoki Togashi</dc:creator>
<dc:creator>Satoru N Takeda</dc:creator>
<dc:creator>Takafumi Hiramoto</dc:creator>
<dc:creator>Satoshi Tasaka</dc:creator>
<dc:creator>Hisato Hirano</dc:creator>
<dc:creator>Takeshi Tokuyama</dc:creator>
<dc:creator>Hideki Uosaki</dc:creator>
<dc:creator>Soh Ishiguro</dc:creator>
<dc:creator>Madina Kagieva</dc:creator>
<dc:creator>Hiroyuki Yamano</dc:creator>
<dc:creator>Yuki Ozaki</dc:creator>
<dc:creator>Daisuke Motooka</dc:creator>
<dc:creator>Hideto Mori</dc:creator>
<dc:creator>Yuhei Kirita</dc:creator>
<dc:creator>Yoshiaki Kise</dc:creator>
<dc:creator>Yuzuru Itoh</dc:creator>
<dc:creator>Satoaki Matoba</dc:creator>
<dc:creator>Hiroyuki Aburatani</dc:creator>
<dc:creator>Nozomu Yachie</dc:creator>
<dc:creator>Tautvydas Karvelis</dc:creator>
<dc:creator>Virginijus Siksnys</dc:creator>
<dc:creator>Tsukasa Ohmori</dc:creator>
<dc:creator>Atsushi Hoshino</dc:creator>
<dc:creator>Osamu Nureki</dc:creator>
<dc:date>2023-09-30</dc:date>
<dc:source>Cell</dc:source>
<dc:title>An AsCas12f-based compact genome-editing tool derived by deep mutational scanning and structural analysis</dc:title>
<dc:identifier>pmid:37776859</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.031</dc:identifier>
</item>
<item>
<title>Multi-omics analysis of mucosal and systemic immunity to SARS-CoV-2 after birth</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37776858/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231003141039&amp;v=2.17.9.post6+86293ac
      <description>The dynamics of immunity to infection in infants remain obscure. Here, we used a multi-omics approach to perform a longitudinal analysis of immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in infants and young children by analyzing blood samples and weekly nasal swabs collected before, during, and after infection with Omicron and non-Omicron variants. Infection stimulated robust antibody titers that, unlike in adults, showed no sign of decay for up to 300 days. Infants...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 26:S0092-8674(23)00978-9. doi: 10.1016/j.cell.2023.08.044. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The dynamics of immunity to infection in infants remain obscure. Here, we used a multi-omics approach to perform a longitudinal analysis of immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in infants and young children by analyzing blood samples and weekly nasal swabs collected before, during, and after infection with Omicron and non-Omicron variants. Infection stimulated robust antibody titers that, unlike in adults, showed no sign of decay for up to 300 days. Infants mounted a robust mucosal immune response characterized by inflammatory cytokines, interferon (IFN) α, and T helper (Th) 17 and neutrophil markers (interleukin [IL]-17, IL-8, and CXCL1). The immune response in blood was characterized by upregulation of activation markers on innate cells, no inflammatory cytokines, but several chemokines and IFNα. The latter correlated with viral load and expression of interferon-stimulated genes (ISGs) in myeloid cells measured by single-cell multi-omics. Together, these data provide a snapshot of immunity to infection during the initial weeks and months of life.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37776858/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231003141039&v=2.17.9.post6+86293ac">37776858</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.044>10.1016/j.cell.2023.08.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37776858</guid>
<pubDate>Sat, 30 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Florian Wimmers</dc:creator>
<dc:creator>Allison R Burrell</dc:creator>
<dc:creator>Yupeng Feng</dc:creator>
<dc:creator>Hong Zheng</dc:creator>
<dc:creator>Prabhu S Arunachalam</dc:creator>
<dc:creator>Mengyun Hu</dc:creator>
<dc:creator>Sara Spranger</dc:creator>
<dc:creator>Lindsay E Nyhoff</dc:creator>
<dc:creator>Devyani Joshi</dc:creator>
<dc:creator>Meera Trisal</dc:creator>
<dc:creator>Mayanka Awasthi</dc:creator>
<dc:creator>Lorenza Bellusci</dc:creator>
<dc:creator>Usama Ashraf</dc:creator>
<dc:creator>Sangeeta Kowli</dc:creator>
<dc:creator>Katherine C Konvinse</dc:creator>
<dc:creator>Emily Yang</dc:creator>
<dc:creator>Michael Blanco</dc:creator>
<dc:creator>Kathryn Pellegrini</dc:creator>
<dc:creator>Gregory Tharp</dc:creator>
<dc:creator>Thomas Hagan</dc:creator>
<dc:creator>R Sharon Chinthrajah</dc:creator>
<dc:creator>Tran T Nguyen</dc:creator>
<dc:creator>Alba Grifoni</dc:creator>
<dc:creator>Alessandro Sette</dc:creator>
<dc:creator>Kari C Nadeau</dc:creator>
<dc:creator>David B Haslam</dc:creator>
<dc:creator>Steven E Bosinger</dc:creator>
<dc:creator>Jens Wrammert</dc:creator>
<dc:creator>Holden T Maecker</dc:creator>
<dc:creator>Paul J Utz</dc:creator>
<dc:creator>Taia T Wang</dc:creator>
<dc:creator>Surender Khurana</dc:creator>
<dc:creator>Purvesh Khatri</dc:creator>
<dc:creator>Mary A Staat</dc:creator>
<dc:creator>Bali Pulendran</dc:creator>
<dc:date>2023-09-30</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Multi-omics analysis of mucosal and systemic immunity to SARS-CoV-2 after birth</dc:title>
<dc:identifier>pmid:37776858</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.044</dc:identifier>
</item>
<item>
<title>Sex-specific and ethnicity-specific differences in MINOCA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37775559/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231003141039&amp;v=2.17.9.post6+86293ac
      <description>Suspected myocardial infarction with non-obstructive coronary arteries (MINOCA) has received increasing attention over the past decade. Given the heterogeneity in the mechanisms underlying acute myocardial infarction in the absence of obstructive coronary arteries, the syndrome of MINOCA is considered a working diagnosis that requires further investigation after diagnostic angiography studies have been performed, including coronary magnetic resonance angiography and functional angiography....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Sep 29. doi: 10.1038/s41569-023-00927-6. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Suspected myocardial infarction with non-obstructive coronary arteries (MINOCA) has received increasing attention over the past decade. Given the heterogeneity in the mechanisms underlying acute myocardial infarction in the absence of obstructive coronary arteries, the syndrome of MINOCA is considered a working diagnosis that requires further investigation after diagnostic angiography studies have been performed, including coronary magnetic resonance angiography and functional angiography. Although once considered an infrequent and low-risk form of myocardial infarction, recent data have shown that the prognosis of MINOCA is not as benign as previously assumed. However, despite increasing awareness of the condition, many questions remain regarding the diagnosis, risk stratification and treatment of MINOCA. Women seem to be more susceptible to MINOCA, but studies on the sex-specific differences of the disease are scarce. Similarly, ethnicity-specific factors might explain discrepancies in the observed prevalence or underlying pathophysiological mechanisms of MINOCA but data are also scarce. Therefore, in this Review, we provide an update on the latest evidence available on the sex-specific and ethnicity-specific differences in the clinical features, pathophysiological mechanisms, treatment and prognosis of MINOCA.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37775559/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231003141039&v=2.17.9.post6+86293ac">37775559</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00927-6>10.1038/s41569-023-00927-6</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37775559</guid>
<pubDate>Fri, 29 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Sarena La</dc:creator>
<dc:creator>John Beltrame</dc:creator>
<dc:creator>Rosanna Tavella</dc:creator>
<dc:date>2023-09-29</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Sex-specific and ethnicity-specific differences in MINOCA</dc:title>
<dc:identifier>pmid:37775559</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00927-6</dc:identifier>
</item>
<item>
<title>Synthetic Par polarity induces cytoskeleton asymmetry in unpolarized mammalian cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37774705/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231003141039&amp;v=2.17.9.post6+86293ac
      <description>Polarized cells rely on a polarized cytoskeleton to function. Yet, how cortical polarity cues induce cytoskeleton polarization remains elusive. Here, we capitalized on recently established designed 2D protein arrays to ectopically engineer cortical polarity of virtually any protein of interest during mitosis in various cell types. This enables direct manipulation of polarity signaling and the identification of the cortical cues sufficient for cytoskeleton polarization. Using this assay, we...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 20:S0092-8674(23)00968-6. doi: 10.1016/j.cell.2023.08.034. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Polarized cells rely on a polarized cytoskeleton to function. Yet, how cortical polarity cues induce cytoskeleton polarization remains elusive. Here, we capitalized on recently established designed 2D protein arrays to ectopically engineer cortical polarity of virtually any protein of interest during mitosis in various cell types. This enables direct manipulation of polarity signaling and the identification of the cortical cues sufficient for cytoskeleton polarization. Using this assay, we dissected the logic of the Par complex pathway, a key regulator of cytoskeleton polarity during asymmetric cell division. We show that cortical clustering of any Par complex subunit is sufficient to trigger complex assembly and that the primary kinetic barrier to complex assembly is the relief of Par6 autoinhibition. Further, we found that inducing cortical Par complex polarity induces two hallmarks of asymmetric cell division in unpolarized mammalian cells: spindle orientation, occurring via Par3, and central spindle asymmetry, depending on aPKC activity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37774705/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231003141039&v=2.17.9.post6+86293ac">37774705</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.034>10.1016/j.cell.2023.08.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37774705</guid>
<pubDate>Fri, 29 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Joseph L Watson</dc:creator>
<dc:creator>Lara K Krüger</dc:creator>
<dc:creator>Ariel J Ben-Sasson</dc:creator>
<dc:creator>Alice Bittleston</dc:creator>
<dc:creator>Marta N Shahbazi</dc:creator>
<dc:creator>Vicente Jose Planelles-Herrero</dc:creator>
<dc:creator>Joseph E Chambers</dc:creator>
<dc:creator>James D Manton</dc:creator>
<dc:creator>David Baker</dc:creator>
<dc:creator>Emmanuel Derivery</dc:creator>
<dc:date>2023-09-29</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Synthetic Par polarity induces cytoskeleton asymmetry in unpolarized mammalian cells</dc:title>
<dc:identifier>pmid:37774705</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.034</dc:identifier>
</item>
<item>
<title>A widely distributed gene cluster compensates for uricase loss in hominids</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37774682/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231003141039&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 28;186(20):4472-4473. doi: 10.1016/j.cell.2023.08.036.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37774682/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231003141039&v=2.17.9.post6+86293ac">37774682</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.036>10.1016/j.cell.2023.08.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37774682</guid>
<pubDate>Fri, 29 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Yuanyuan Liu</dc:creator>
<dc:creator>J Bryce Jarman</dc:creator>
<dc:creator>Yen S Low</dc:creator>
<dc:creator>Hannah E Augustijn</dc:creator>
<dc:creator>Steven Huang</dc:creator>
<dc:creator>Haoqing Chen</dc:creator>
<dc:creator>Mary E DeFeo</dc:creator>
<dc:creator>Kazuma Sekiba</dc:creator>
<dc:creator>Bi-Huei Hou</dc:creator>
<dc:creator>Xiandong Meng</dc:creator>
<dc:creator>Allison M Weakley</dc:creator>
<dc:creator>Ashley V Cabrera</dc:creator>
<dc:creator>Zhiwei Zhou</dc:creator>
<dc:creator>Gilles van Wezel</dc:creator>
<dc:creator>Marnix H Medema</dc:creator>
<dc:creator>Calyani Ganesan</dc:creator>
<dc:creator>Alan C Pao</dc:creator>
<dc:creator>Saurabh Gombar</dc:creator>
<dc:creator>Dylan Dodd</dc:creator>
<dc:date>2023-09-29</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A widely distributed gene cluster compensates for uricase loss in hominids</dc:title>
<dc:identifier>pmid:37774682</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.036</dc:identifier>
</item>
<item>
<title>Early Alzheimer's disease pathology in human cortex involves transient cell states</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37774681/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231003141039&amp;v=2.17.9.post6+86293ac
      <description>Cellular perturbations underlying Alzheimer's disease (AD) are primarily studied in human postmortem samples and model organisms. Here, we generated a single-nucleus atlas from a rare cohort of cortical biopsies from living individuals with varying degrees of AD pathology. We next performed a systematic cross-disease and cross-species integrative analysis to identify a set of cell states that are specific to early AD pathology. These changes-which we refer to as the early cortical amyloid...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 28;186(20):4438-4453.e23. doi: 10.1016/j.cell.2023.08.005.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cellular perturbations underlying Alzheimer's disease (AD) are primarily studied in human postmortem samples and model organisms. Here, we generated a single-nucleus atlas from a rare cohort of cortical biopsies from living individuals with varying degrees of AD pathology. We next performed a systematic cross-disease and cross-species integrative analysis to identify a set of cell states that are specific to early AD pathology. These changes-which we refer to as the early cortical amyloid response-were prominent in neurons, wherein we identified a transitional hyperactive state preceding the loss of excitatory neurons, which we confirmed by acute slice physiology on independent biopsy specimens. Microglia overexpressing neuroinflammatory-related processes also expanded as AD pathology increased. Finally, both oligodendrocytes and pyramidal neurons upregulated genes associated with β-amyloid production and processing during this early hyperactive phase. Our integrative analysis provides an organizing framework for targeting circuit dysfunction, neuroinflammation, and amyloid production early in AD pathogenesis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37774681/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231003141039&v=2.17.9.post6+86293ac">37774681</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.005>10.1016/j.cell.2023.08.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37774681</guid>
<pubDate>Fri, 29 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Vahid Gazestani</dc:creator>
<dc:creator>Tushar Kamath</dc:creator>
<dc:creator>Naeem M Nadaf</dc:creator>
<dc:creator>Antonios Dougalis</dc:creator>
<dc:creator>S J Burris</dc:creator>
<dc:creator>Brendan Rooney</dc:creator>
<dc:creator>Antti Junkkari</dc:creator>
<dc:creator>Charles Vanderburg</dc:creator>
<dc:creator>Anssi Pelkonen</dc:creator>
<dc:creator>Mireia Gomez-Budia</dc:creator>
<dc:creator>Nelli-Noora Välimäki</dc:creator>
<dc:creator>Tuomas Rauramaa</dc:creator>
<dc:creator>Martine Therrien</dc:creator>
<dc:creator>Anne M Koivisto</dc:creator>
<dc:creator>Matthew Tegtmeyer</dc:creator>
<dc:creator>Sanna-Kaisa Herukka</dc:creator>
<dc:creator>Abdulraouf Abdulraouf</dc:creator>
<dc:creator>Samuel E Marsh</dc:creator>
<dc:creator>Mikko Hiltunen</dc:creator>
<dc:creator>Ralda Nehme</dc:creator>
<dc:creator>Tarja Malm</dc:creator>
<dc:creator>Beth Stevens</dc:creator>
<dc:creator>Ville Leinonen</dc:creator>
<dc:creator>Evan Z Macosko</dc:creator>
<dc:date>2023-09-29</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Early Alzheimer's disease pathology in human cortex involves transient cell states</dc:title>
<dc:identifier>pmid:37774681</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.005</dc:identifier>
</item>
<item>
<title>Epigenomic dissection of Alzheimer's disease pinpoints causal variants and reveals epigenome erosion</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37774680/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231003141039&amp;v=2.17.9.post6+86293ac
      <description>Recent work has identified dozens of non-coding loci for Alzheimer's disease (AD) risk, but their mechanisms and AD transcriptional regulatory circuitry are poorly understood. Here, we profile epigenomic and transcriptomic landscapes of 850,000 nuclei from prefrontal cortexes of 92 individuals with and without AD to build a map of the brain regulome, including epigenomic profiles, transcriptional regulators, co-accessibility modules, and peak-to-gene links in a cell-type-specific manner. We...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 28;186(20):4422-4437.e21. doi: 10.1016/j.cell.2023.08.040.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Recent work has identified dozens of non-coding loci for Alzheimer's disease (AD) risk, but their mechanisms and AD transcriptional regulatory circuitry are poorly understood. Here, we profile epigenomic and transcriptomic landscapes of 850,000 nuclei from prefrontal cortexes of 92 individuals with and without AD to build a map of the brain regulome, including epigenomic profiles, transcriptional regulators, co-accessibility modules, and peak-to-gene links in a cell-type-specific manner. We develop methods for multimodal integration and detecting regulatory modules using peak-to-gene linking. We show AD risk loci are enriched in microglial enhancers and for specific TFs including SPI1, ELF2, and RUNX1. We detect 9,628 cell-type-specific ATAC-QTL loci, which we integrate alongside peak-to-gene links to prioritize AD variant regulatory circuits. We report differential accessibility of regulatory modules in late AD in glia and in early AD in neurons. Strikingly, late-stage AD brains show global epigenome dysregulation indicative of epigenome erosion and cell identity loss.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37774680/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231003141039&v=2.17.9.post6+86293ac">37774680</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.040>10.1016/j.cell.2023.08.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37774680</guid>
<pubDate>Fri, 29 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Xushen Xiong</dc:creator>
<dc:creator>Benjamin T James</dc:creator>
<dc:creator>Carles A Boix</dc:creator>
<dc:creator>Yongjin P Park</dc:creator>
<dc:creator>Kyriaki Galani</dc:creator>
<dc:creator>Matheus B Victor</dc:creator>
<dc:creator>Na Sun</dc:creator>
<dc:creator>Lei Hou</dc:creator>
<dc:creator>Li-Lun Ho</dc:creator>
<dc:creator>Julio Mantero</dc:creator>
<dc:creator>Aine Ni Scannail</dc:creator>
<dc:creator>Vishnu Dileep</dc:creator>
<dc:creator>Weixiu Dong</dc:creator>
<dc:creator>Hansruedi Mathys</dc:creator>
<dc:creator>David A Bennett</dc:creator>
<dc:creator>Li-Huei Tsai</dc:creator>
<dc:creator>Manolis Kellis</dc:creator>
<dc:date>2023-09-29</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Epigenomic dissection of Alzheimer's disease pinpoints causal variants and reveals epigenome erosion</dc:title>
<dc:identifier>pmid:37774680</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.040</dc:identifier>
</item>





























</channel>
</rss>